6,678 trials
Drug Therapy, Combination
Primary: Area Under the Plasma Effect-time Curve Over 96 Hours (AUEC[0-96 h]) for International Normalized Ratio (INR) — -2.16; -9.06 hours*ratio
Renal Insufficiency, Chronic
Primary: Change in Flow-mediated Dilation (FMD) — 1.1; -0.9 change in percent flow-mediated dilation
Transplantation · Immunosuppression · Drug Interaction
Primary: Dose-normalized AUC of Mycophenolic Acid — 41; 38; 43; 46 mg*h/L
Acne
Primary: Mean Rate of Adherence, as Assessed by Medical Event Monitoring System (MEMS) — 63.1; 56.5; 48.2 percentage of adherence — p=0.3165
Perimenopausal Depression · Depression
Primary: Center for Epidemiologic Studies-Depression Scale (CES-D) — 27.4; 29.1; 28.8; 24.6 Units on a scale
Diabetes Mellitus, Type 2
Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26 — -0.01; -0.91 percentage of glycosylated hemoglobin
Cerebral Arterial Aneurysm
Primary: Evidences of Clinically Definite Oxidative Stress Confirmed by ELISA Kit — 72.87; 74.02; 67.10; 65.91 U/ml
Epilepsy · Cognitive Deficits · Attention Deficits
Primary: Conners' Continuous Performance Test (CPT) (Double-blind Portion, Primary Variables) — -3.3; -3.58; -3.66; 0.19 Units — p=0.037
Schizophrenia
Primary: Percentage of Participants That Responded to Treatment — 62.8; 56.8 percentage of response — p=.61
Pain
Primary: Time to Significant Increase in Local Surface Temperature
Parkinson's Disease
Primary: Change From Baseline to End of Study — 64; 18.5 Percentage of participants
Peripheral Arterial Diseases
Primary: Binary Restenosis — 22.8 percentage of patients
Postoperative Respiratory Condition
Primary: Mean Lowest Saturation — 96.8; 93.3 percentage of oxygen saturation
Premenstrual Dysphoric Disorder
Primary: Pre-Post Change in Premenstrual Symptom Severity — 1.93; 1.73; 1.64 units on a scale
Coronary Occlusion · Thrombosis (Stent Thrombosis) · Vascular Disease
Primary: In-stent Late Loss (LL) — 0.19; 0.21 Millimeter